All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @sirmixaflock on TikTok · 109s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @sirmixaflock's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm a 38 year old man who's been taking compound semaglutide for the past five and a half months
  2. 0:04compound semaglutide being what is found in Ozempic and wagovii and my skin and my hair
  3. 0:12are better than they've been in my entire life. Let's talk about it. One of the biggest concerns
  4. 0:17for people is Ozempic face and what it does to your skin and to your hair. Let me just say that my
  5. 0:25skin my entire life has always been an issue. I have not liked my skin. At the start of this year
  6. 0:31I decided I was going to do less for my skin. I used to have all kinds of stuff in my routine
  7. 0:37and my skin was always dry or always oily. I never figured out I just said screw it I'm just
  8. 0:42going to put water and rose water on my face and if I break out I'll do a patch or something like that.
  9. 0:48And interestingly enough my skin has improved. It's not perfect as you can see. I've got some stuff
  10. 0:54going on but so much better than it was even two years ago. My hair unlike my midsection is thick
  11. 1:02and luscious. I'm telling you this because a lot of people have commented about Ozempic face
  12. 1:08what it does to your skin what it does to your hair and I have seen no change. That's not good
  13. 1:14it's not bad it's just neutral. My skin hasn't gotten better because of Ozempic it got better
  14. 1:19because I stopped using a whole bunch of crap on it every single day. And my hair hasn't gotten
  15. 1:24worse because Ozempic it's just stayed as awesome as it always is. I mean it's unruly and I don't know
  16. 1:30how to style it but god damn is there a lot of it. So hopefully this relates even more of your fears
  17. 1:36on GLP1 receptor agonist and gets you to take the leap to talk to your doctor about it if you've
  18. 1:41been on the fence and have been considering it for your medical or your cosmetic weight loss journey.
  19. 1:47I'm here for your comments.

Can semaglutide improve skin and hair? We fact-checked Evan's claims

Evan

TikTok creator

206.3K viewsWatch on TikTok

Quick answer

Telogen effluvium secondary to rapid weight loss is a documented adverse effect associated with GLP-1 receptor agonist therapy, appearing in roughly 3% of participants in the STEP 1 trial for semaglutide. Facial volume changes often labeled 'Ozempic face' are primarily driven by the rate and extent of total weight loss rather than a direct pharmacological effect of semaglutide on skin tissue. Patients using compounded semaglutide should be counseled that compounded formulations have not undergone FDA review for purity, potency, or clinical equivalence to approved branded products.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Can semaglutide improve skin and hair? We fact-checked Evan's claims, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Can semaglutide improve skin and hair? We fact-checked Evan's claims" from Evan. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Telogen effluvium secondary to rapid weight loss is a documented adverse effect associated with GLP-1 receptor agonist therapy, appearing in roughly 3% of participants in the STEP 1 trial for semaglutide.

The reason this review is not generic is the source wording and the canonical claim label "glp1 what 6 months of semaglutide has done to my skin and hair." In this clip, the useful excerpt is: "I'm a 38 year old man who's been taking compound semaglutide for the past five and a half months compound semaglutide being what is found in Ozempic and wagovii and my skin and my hair are better than they've been in my entire life." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Facial volume changes associated with GLP-1 medications are driven primarily by the rate and magnitude of total weight loss, not a direct drug effect on skin structure.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Telogen effluvium secondary to rapid weight loss is a documented adverse effect associated with GLP-1 receptor agonist therapy, appearing in roughly 3% of participants in the STEP 1 trial for semaglutide.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Telogen effluvium secondary to rapid weight loss is a documented adverse effect associated with GLP-1 receptor agonist therapy, appearing in roughly 3% of participants in the STEP 1 trial for semaglutide. Facial volume changes often labeled 'Ozempic face' are primarily driven by the rate and extent of total weight loss rather than a direct pharmacological effect of semaglutide on skin tissue. Patients using compounded semaglutide should be counseled that compounded formulations have not undergone FDA review for purity, potency, or clinical equivalence to approved branded products.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found alopecia in roughly 3% of semaglutide participants versus 1% in placebo, so hair loss is a documented signal, not just a social media scare.
  • Facial volume changes associated with GLP-1 medications are driven primarily by the rate and magnitude of total weight loss, not a direct drug effect on skin structure.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found alopecia in roughly 3% of semaglutide participants versus 1% in placebo, so hair loss is a documented signal, not just a social media scare.
  • Facial volume changes associated with GLP-1 medications are driven primarily by the rate and magnitude of total weight loss, not a direct drug effect on skin structure.
  • Telogen effluvium from rapid weight loss typically peaks three to four months in and is usually self-limiting, but it is more likely in people losing weight quickly or those with lower nutritional reserves.
  • Compounded semaglutide is not FDA-reviewed for safety or efficacy and cannot be assumed equivalent to brand-name Ozempic or Wegovy, regardless of active ingredient similarity.
  • Skin barrier improvement from reducing product overload is well-supported in dermatology literature and is a plausible explanation for this creator's results independent of any drug effect.
  • One creator's positive cosmetic outcome at six months is a single data point. Sex, age, rate of weight loss, and hormonal status all influence how individuals respond to GLP-1-associated body composition changes.
  • If hair shedding is a concern before starting a GLP-1 medication, adequate protein intake during weight loss is one of the few evidence-adjacent strategies worth discussing with your provider proactively.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @sirmixaflock actually say?

After five and a half months on compounded semaglutide, this creator says his skin and hair are "better than they've been in my entire life." He's careful to separate cause from effect, crediting his skin improvement to simplifying his skincare routine, not the drug itself. His hair, he says, is unchanged. His core message: GLP-1 side effects on skin and hair are overhyped, and his experience was essentially neutral. He's not claiming semaglutide gave him a glow-up. He's saying it didn't wreck him either.

That's actually a more honest framing than you see from a lot of TikTok GLP-1 content. He's not selling a miracle. He acknowledges his skin improvement came from doing less, not from Ozempic. For a 206K-view video, that's a refreshingly grounded take.

Does the science back this up?

Mostly, yes, with some important nuance he didn't mention. The "Ozempic face" concern is real but often misattributed. The issue isn't the drug itself, it's rapid fat loss redistributing or reducing facial volume. Whether that happens depends heavily on how much weight you lose and how fast.

On hair loss specifically, the picture is more complicated than his experience suggests. Telogen effluvium, a condition where significant physiological stress pushes hair follicles into a resting phase and triggers shedding, is a known consequence of rapid weight loss regardless of the method. A 2023 analysis of FDA Adverse Event Reporting System data flagged hair loss signals for semaglutide and liraglutide. The STEP 1 trial (Wilding et al., 2021, NEJM) reported alopecia in roughly 3% of semaglutide participants versus about 1% in the placebo group. That gap matters. His hair being fine is genuinely good news for him, but it's not a universal promise.

What did they get wrong (or right)?

He got the core attribution right: his skin improving after stripping back his routine is entirely plausible. Over-cleansing and layering too many actives is a well-documented cause of barrier disruption. The American Academy of Dermatology has published guidance on this for years. Giving semaglutide credit for that would have been wrong, and he didn't.

What he underplays is that hair loss on GLP-1 medications is not purely a myth. He says his hair "hasn't gotten worse," which is his honest personal experience. But framing this as something that should "ease your fears" about GLP-1s broadly is where the video oversimplifies. The shedding risk is real, especially in the first three to six months of significant weight loss. It's usually temporary, but temporary doesn't mean trivial. He also doesn't mention that his being male and 38 with "thick and luscious" hair may simply mean he's starting from a position of lower vulnerability to telogen effluvium than, say, a postmenopausal woman on the same drug.

What should you actually know?

"Ozempic face" is a real phenomenon but it's really "rapid-weight-loss face." It's not unique to semaglutide, and it's not guaranteed. Facial volume loss tracks with total weight lost, not with the drug specifically. Slower weight loss curves tend to produce less dramatic changes.

Hair shedding is a documented risk, not a social media myth. If it happens, it typically peaks around three to four months into significant weight loss and resolves on its own. Adequate protein intake during weight loss is one of the few evidence-adjacent strategies for minimizing it. One creator having great hair at six months is a data point of one.

His advice to talk to your doctor is the right call. His personal results, while positive, don't predict yours. Skin type, rate of weight loss, starting BMI, hormonal status, and baseline hair density all affect how your body responds. What he experienced is possible. So is something different.

  • Compounded semaglutide is not the same product as FDA-approved branded medications. The FDA has not evaluated compounded versions for safety or efficacy.
  • If you're concerned about hair changes on a GLP-1 medication, ask your provider before starting, not after you notice the shower drain.

Bottom line

This video is more honest than most GLP-1 content on TikTok. The creator correctly avoids crediting semaglutide for his skin improvements and doesn't dramatize side effects he didn't experience. But one person's neutral experience doesn't neutralize documented risks. Hair loss on GLP-1 medications has a real signal in the literature and a plausible biological mechanism. His experience is valid. It's just not the whole story.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Evan · TikTok creator

206.3K views on this video

What 6 months of semaglutide has done to my skin and hair

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found alopecia in roughly 3% of semaglutide participants versus 1% in placebo, so hair loss is a documented signal, not just a social media scare.

What does the video say about facial volume changes associated with glp-1 medications?

Facial volume changes associated with GLP-1 medications are driven primarily by the rate and magnitude of total weight loss, not a direct drug effect on skin structure.

What does the video say about telogen effluvium from rapid weight loss typically peaks three to?

Telogen effluvium from rapid weight loss typically peaks three to four months in and is usually self-limiting, but it is more likely in people losing weight quickly or those with lower nutritional reserves.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-reviewed for safety or efficacy and cannot be assumed equivalent to brand-name Ozempic or Wegovy, regardless of active ingredient similarity.

What does the video say about skin barrier improvement from reducing product overload?

Skin barrier improvement from reducing product overload is well-supported in dermatology literature and is a plausible explanation for this creator's results independent of any drug effect.

What does the video say about one creator's positive cosmetic outcome at six months?

One creator's positive cosmetic outcome at six months is a single data point. Sex, age, rate of weight loss, and hormonal status all influence how individuals respond to GLP-1-associated body composition changes.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Evan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.